Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including lamivudine- resistant strains

Korean Journal of Internal Medicine

Volumn 27, Issue 4, 2012, Pages 411-416

  Sun, In O ^a   Hong, Yu Ah ^a   Park, Hoon Suk ^a   Choi, Sun Ryoung ^a   Chung, Byung Ha ^a   Park, Cheol Whee ^a   Yang, Chul Woo ^a   Kim, Yong Soo ^a   Choi, Bum Soon ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Hepatitis B; Membranous glomerulonephritis

Indexed keywords

ADEFOVIR DIPIVOXIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIVIRUS AGENT; CLEVUDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SUBSTITUTION; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; INCIDENCE; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MYOPATHY; NONHUMAN; PROGNOSIS; REMISSION; SEROCONVERSION; TREATMENT RESPONSE; VIRUS STRAIN;

HEPATITIS B; MEMBRANOUS GLOMERULONEPHRITIS;

ADENINE; ADULT; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; DRUG RESISTANCE, VIRAL; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; YOUNG ADULT;

EID: 84871731098     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2012.27.4.411     Document Type: Article

References (21)

1. Jefferson JA, Couser WG. Therapy of membranous nephropathy associated with malignancy and secondary causes. Semin Nephrol 2003;23:400-405.
2. Zeng CH, Chen HM, Wang RS, et al. Etiology and clinical characteristics of membranous nephropathy in Chinese patients. Am J Kidney Dis 2008;52:691-698.
3. Lee EJ, Lee SH, Won JJ, et al. Etiology and clinical course of secondary membranous nephropathy. Korean J Med 2005;68:407-416.
4. Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991;324:1457-1463.
5. Lai KN, Tam JS, Lin HJ, Lai FM. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron 1990;54:12-17.
6. Conjeevaram HS, Hoofnagle JH, Austin HA, Park Y, Fried MW, Di Bisceglie AM. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology 1995;109:540-546.
7. Tang S, Lai FM, Lui YH, et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005;68:1750-1758.
8. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B:Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-180.
9. Allen MI, Gauthier J, DesLauriers M, et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999;37:3338-3347.
10. Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001;59:1484-1490.
11. Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over two decades. J Gastroenterol Hepatol 2011;26 Suppl 1:138-143.
12. Yi Z, Jie YW, Nan Z. The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: a systematic review and meta-analysis. Ann Hepatol 2011;10:165-173.
13. Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-834.
14. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539.
15. Fu L, Liu SH, Cheng YC. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem Pharmacol 1999;57:1351-1359.
16. Tak WY, Park SY, Cho CM, et al. Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. J Hepatol 2010;53:261-266.
17. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.
18. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514.
19. Ikee R, Ishioka K, Oka M, et al. Hepatitis B virus-related membranous nephropathy treated with entecavir. Nephrology (Carlton) 2010;15:266.
20. Lai AS, Lai KN. Viral nephropathy. Nat Clin Pract Nephrol 2006;2:254-262.
21. Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990;37:663-676.